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1. Introduction 
Oxidative stress has long been associated with cardiovascular disease (CVD) (Abuja & 
Albertini, 2001; Halliwell & Gutteridge, 1990; Parthasarathy et al., 2001; Steinbrecher et al., 
1984). It was even assumed that the prevalence of CVD alone indicates the prevalence of 
oxidative stress (Witztum, 1994). Moreover, cross-sectional studies indicated that 
supplementation of low molecular weight antioxidants is associated with a relatively low 
incidence of CVD (Jha et al., 1995). By contrast, in most of the interventional studies the 
antioxidant supplementation did not prevent the progression of CVD nor did it improve 
any of the many clinical endpoints (Shekelle et al., 2004; Vivekananthan et al., 2003; Miller 
2005; Bjelakovic, 2007; Dotan, 2009a; Dotan, 2009b). Based on these findings, Witztum 
(Witztum, 1998) and Morrow (Morrow, 2003) hypothesized that only individuals under 
oxidative stress may benefit from antioxidant supplementation. This, of course, implies that 
only people under oxidative stress should be treated with antioxidants. This, in turn, means 
that a criterion must be established for the ill-defined, intuitively understood term 
“oxidative stress”. 
This issue is of special importance in light of our previous study that demonstrated that no 
single index can be used as a universal criterion, indicating that there are several types of 
oxidative stress (Dotan et al., 2004). Hence, the question remains which criterion (or criteria) 
can be used to identify who is likely to benefit from antioxidant supplementation. The 
answer to this question can, theoretically, be based either on a criterion for the relevant type 
of oxidative stress (e.g. lipid peroxidation, as assessed by the concentrations of MDA or 
isoprostanes) or/and on diagnosis of specific diseases for which there is sufficient evidence 
for benefit of antioxidant supplementation. 
In the current study, we present the results of a meta-analysis of case-control studies used to 
assess the association between CVD and oxidative stress, as evaluated on the basis of 
different criteria. Unlike previous meta-analyses, we analyzed the association between CVD 
and criteria for each of the types of OS. We hope that eventually this analysis will enable us 
to define threshold values of relevant indices of the relevant type of oxidative stress for 
treatment with antioxidants (Deeks, 2001; Deeks & Altman, 2004). 
2. Methods 
This work was performed according to the guidelines outlined by the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) group (Stroup et al., 2000). A detailed 
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description of the data retrieval process, the selection criteria and the analyses of the data is 
given in the following subsections. 
2.1 Retrieval and selection of studies to be included in the analysis 
First, we had to define criteria to be used in our search for clinical trials to be included in our 
meta-analysis (Fig. 1). The following criteria were defined for our search: 
i. Design: only case-control or nested case control studies were included.  
ii. Methods: for a clinical study to be included in our meta-analysis it had to use only 
generally accepted methods for the evaluation of oxidative stress (Dotan et al., 2004). 
iii. Size: to be included in our meta-analysis, the study had to involve at least 20 CVD 
patients and at least 20 “CVD-free” individuals, serving as a control group. 
The latter demand requires further definition of the two populations that can be regarded as 
being “CVD patients” and their respective controls. We included in the control group only 
“pathology-free” individuals. To be included in the group of “CVD patients”, a person had 
to be diagnosed with one of the following conditions: (i) either stable angina pectoris (STP) 
or unstable angina pectoris (UTP), diagnosed either by angiogram or by physical 
examination, (ii) patients suffering from any of the stages of coronary stenosis and (iii) a 
recorded history of CVD (e.g. myocardial infraction). 
With these criteria in mind, we searched through two major databases, namely, the Medline 
database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed) 
and the Thomson Reuters ISI Web of Science. Reference mining was conducted to find an 
arbitrarily predefined number of studies (20) that fit all the above selection criteria. We 
defined a list of keywords to search and conducted a simple keyword search, similar to that 
described by Shekelle et al. (Shekelle et al., 2004). 
Data of case-control studies may be biased towards the prevailing paradigm and the 
findings of other recent trials (French et al., 2005; Moher & Tsertsvadze, 2006). Such bias 
must be considered when conducting a search for studies to be included in meta-analyses 
because it may cause a change in the significance of the pooled variables (French et al., 2005; 
Moher & Tsertsvadze, 2006). This is of special importance in the present meta-analysis 
because the prevailing paradigm changed from viewing “oxidative stress” as a cause of 
atherosclerosis (Witztum, 1994) to viewing it as being merely a result of questionable 
significance (Witztum & Steinberg, 2001). In addition, we had to assess the completeness of 
the retrieved data and its validity with respect to the complete body of published data 
(Bennett et al., 2004). Towards this end, we have devised an algorithm similar to the 
“capture-recapture technique” proposed by Spoor et al. (Spoor et al., 1996). Spoor et al. used 
different methods of data retrieval to assess their results. We used, for the same purpose, 
different time frames. Briefly, to achieve as random as possible subset of studies (Furukawa 
et al., 2002), we searched the Medline database to identify studies published between 
1.1.1990 and 1.8.2003 and used studies dating from 1.8.2003 until 1.2.2006 to reassert our 
findings, as proposed by Moher & Tsertsvadze (Moher & Tsertsvadze, 2006). By that, we 
have minimized the bias towards recent publications. 
2.2 Data analysis 
The difference between individuals with prevalent CVD and their controls, as observed in 
each of the selected studies, was expressed in terms of two factors: (i) the standard mean 
difference (SMD), which is a composite index, and (ii) the 95% confidence interval of the 
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SMD, which reflects both the mean difference and the standard deviation. Our study 
required the use of SMD for two reasons: (i) it allows pooling of results obtained from 
different studies and (ii) its use compensates, at least partially, for the use of different 
methods, different units of measurement and inter-lab differences (Deeks et al., 2001). We 
implemented SMD by using "Hedges' adjusted g" because it contains a correction for small 
sample bias (Bennett et al., 2004). 
 
 
Fig. 1. An outline of the flow of studies in the meta-analyses. We identified many 
publications that contained the required sets of keywords (e.g. [CVD or CHD] and oxidative 
stress). 
To pool our results, we have considered two possible models, namely the “fixed effect 
model”, which assumes that all the studies and trials are the repeating of the same 
experiment (Lau et al., 1998) or the “random effects model” of DerSimonian and Laird, 
which assumes that the clinical trials estimate a different, yet related, variables with a 
common distribution (Higgins et al., 2002; Lau et al., 1998). From these two models, we 
chose to use the random effects model, because we expected heterogeneous results from 
observational studies (Egger et al., 1998). In our view, the “fixed effect model” 
oversimplifies the problem and its accuracy has been questioned by others in the same 
context (Lau et al., 1998), particularly when there was a need to pool results of 
heterogeneous populations (Lau et al., 1998). 
In our analyses of the data, we relate not only to the mean value of the pooled variables. We 
also used the collected data to assess the credibility of the results as previously proposed by 
Smith et al. (Smith et al., 1997). Assessment of heterogeneity in a meta-analysis of 
observational studies is as important as the mean results (Egger et al., 1998; Egger et al., 
1997a). We assessed the heterogeneity in terms of the following indices as proposed by Song 
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(Song et al., 2001): (i) χ² (Deeks et al., 2001), (ii) i² (used by the RevMan 4.2.8 software) and 
(iii) log(χ²/DF+1), where DF is the number of degrees of freedom (Deeks et al., 2001), for 
comparing the degree of heterogeneity between heterogeneous results. 
To detect variables that affect our models, we used stratification, clustering of associated 
variables and meta-regression models (Smith et al., 1997; Song et al., 2001). Yet, unlike in the 
case of clinical trials, we analyzed either the complete trial or a specific subgroup within the 
trial (Lau et al., 1998). We also analyzed the correlations between indices of oxidative stress 
and various stages of CVD, to determine causality (Egger et al., 1998; Mulrow, 1994; Smith et 
al., 1997). To assess the effects of exposure variables on the outcome, we used stratification 
for common risk-related variables such as age (in subgroups), gender and history of 
smoking (Smith et al., 1997; Sterne, et al., 2001). We also used stratification for variables 
specific to the pathology (e.g. stable and unstable angina pectoris in CVD), as proposed by 
Smith et al (Smith et al., 1997). We used meta-regression (logistic and multiple linear) to 
model the increase in continuous and ordinal SMD, as well as the annual event rates (Lau et 
al., 1998). We used the observed SMD as our dependent variable and the covariates of 
interest (independent variables) to assess the sources of heterogeneity (Lau et al., 1998). A 
mixed stepwise regression was used to detect trends and factors affecting SMD of MDA 
concentration in CVD (Lau et al., 1998). 
To detect (and assess) the degree of bias in our meta-analyses, we have used both the "Trim 
and Fill method” (Duval & Tweedie , 2000) and a simple funnel plots (Sutton et al., 2000). A 
funnel plot is a regression of each trial's effect size against a measure of its size (e.g. 
1/standard error) (Sutton et al., 2000). An asymmetry in a forest plot is attributed to the high 
probability that smaller studies with less statistical power are not published. Asymmetric 
publications were "trimmed" and then the number of studies missing was calculated. We 
used a simulation to fill the missing studies as described by Duval & Tweedie (Duval & 
Tweedie, 2000), thus verifying our initial assumption. We used additional methods to assess 
the relations between study size and results, mainly because publication-bias is not the only 
reason for asymmetry in funnel plots, and because this method may be subjective and have 
a relatively high false-positive rate of detecting bias (Sterne et al., 2001). We compensated for 
the subjective nature of graphical assessment by using the rank correlation method 
(Thornton and Lee, 2000) and an adjustment of the “Egger’s method” (Egger et al., 1997b). 
Rank correlation is the statistical analogue of the funnel plot, namely a regression of the 
effect size (SMD) against both sizes of study and 1/SE (Thornton and Lee, 2000). We used an 
adjustment of the “Egger's method” to detect publication bias and its direction. We defined 
the standard normal deviate (SND) as the mean difference, divided by its standard error 
regressed against the estimate's precision (Bennett et al., 2004). We defined the threshold p-
value for the intercept at a value of 0.1 to detect possible bias (Bennett et al., 2004). 
3. Results 
As depicted in Fig. 1, we reviewed 172 studies, of which 20 were selected for analysis. These 
chosen 20 studies compared 1068 CVD patients to 2128 matched controls, using 15 common 
indices to assess oxidative stress. A summary of the results is given in Fig. 2 (Akkus et al., 
1996; Cavalca et al., 2001; Chiu et al., 1994; Cipollone et al., 2000; Clejan et al., 2002; Delanty 
et al., 1997; Durak et al., 2001; Ferns et al., 2000; Gackowski et al., 2001; Haidari et al., 2001; 
Halevy et al., 1997; Karmansky et al., 1996; Kesavulu et al., 2001; Kostner et al., 1997; 
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McMurray et al., 1992; Schisterman et al., 2002; Singh et al., 1995; Tamer et al., 2002; Turgan 
et al., 1999; Weinbrenner et al., 2003). 
 
 
Fig. 2. Indices of oxidative stress in cardiovascular disease. We present both graphically and 
numerically the pooled standardized mean difference (SMD) and the 95% confidence 
interval. Also given is the heterogeneity, as defined by χ²/df + 1, of the studies regarding 
each index. Note that MDA is the only accepted index of oxidative stress that shows a mean 
difference greater the 1SMD. 
Given the prevailing paradigm regarding the association between atherosclerosis and lipid 
peroxidation (Witztum & Steinberg, 2001), it is not surprising that MDA was the most 
frequently used index utilized to assess oxidative stress (13/20 studies). Furthermore, only 
MDA exhibited a strong effect size, given by a SMD of 1.60 (0.75 to 2.45). Using the “Trim 
and Fill” method (Duval & Tweedie, 2000) revealed that at least three studies were missing 
from the funnel plot. Adjusting for the latter finding resulted in a much lower SMD of 0.71 
(0.37 to 1.05). The "Egger method" (Egger et al., 1997b) identified an intercept that was 
significant and positive, supporting the conclusion that the previously observed differences 
were overestimated. 
We performed a mixed stepwise regression for MDA concentrations, factoring in age, 
gender, smoking habits, severity of CVD, prevalence of hypertension and diabetes mellitus 
as well as the use of NSAIDs. This analysis indicated that the inclusion of smokers in both 
CVD patients and control groups (estimate1 = -1.3, p =0.04), results in an underestimation of 
the association between CVD and oxidative stress. By contrast, the inclusion of patients with 
both acute (severe CVD) and chronic (mild CVD) coronary syndromes (estimate =3.1, 
p=0.01), results in an overestimation of the latter associations. 
We stratified the results from those studies that assessed MDA concentrations into three 
groups: (i) patients with unstable angina pectoris (UAP), (ii) patients with stable angina 
                                                 
1Estimate: A numerical value obtained from a statistical sample and assigned to a population 
parameter. 
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pectoris (SAP) and (iii) healthy controls. As seen in Fig. 3, the MDA concentrations of 
patients with SAP are not different from matched controls, whereas UAP patients have 
significantly higher MDA concentrations than both healthy controls and patients with SAP. 
We also stratified the results from two types of studies, those that had acute coronary 
conditions (MI, UAP) and those CVD patients who had chronic coronary conditions (SAP 
and occlusions). As seen in Fig. 4, patients with acute coronary conditions had marked and 
significantly higher MDA concentrations (SMD = 2.30, 0.93 to 3.67) than matched controls. 
By contrast, patients with chronic coronary conditions had only slightly higher MDA 
concentrations (SMD = 0.60,  0.18 to 1.01) as compared with matched controls. 
The concentrations of beta-carotene, as evaluated by Singh et al. (Singh et al., 1995), were 
significantly lower in CVD patients than in matched controls. The difference between the 
concentrations all other low molecular weight antioxidants (LMWA) in patients with CVD and 
healthy controls were not statistically significant (Fig. 2). In six of the seven studies vitamin E 
concentration in CVD patients and controls was similar (SMD = 0.02, -0.17 to 0.21). 
Significantly lower concentrations were observed only by Singh et al. Furthermore, pooling 
the results from all the seven studies failed to achieve statistically significant differences 
(SMD = -0.19, -0.67 to 0.29), although the heterogeneity index substantially increased from 
1.35 to 11.51. The differences between the results of Singh et al. and all other studies cannot 
be attributed either to publication bias or to small-sample bias. A viable possibility is that 
the difference is due to selection bias, particularly by a biased selection of controls. Indeed, 
the major difference between the results obtained by Singh et al. and the results observed in 
all the other studies assessing LMWA was that Singh et al. selected their control group to 
exclude most, if not all of the CVD-related risk factors (smoking, DM and glucose 
intolerance), whereas the CVD patients were not devoid of these risk factors. 
 
 
Fig. 3. A forest plot of studies assessing the differences between patients with stable angina 
pectoris and patients with unstable angina pectoris (upper panel) and comparison of each of 
these groups with controls (two lower panels). 
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Unfortunately, those studies that used either DNA damage or total antioxidant capacity 
(TEAC) to assess oxidative stress in patients with CVD in comparison to healthy controls 
(Fig. 2) were too few and too small to enable any conclusions. 
4. Discussion 
Based on many lines of indirect evidence, oxidative stress has long been associated with CVD. 
The following findings have been considered to lend support to the oxidative theory of CVD: 
(i) oxidized LDL may cause formation of foam cell in-vitro (Chisolm & Steinberg, 2000), (ii) the 
development of atherosclerosis is preceded by an increase of the levels of many indicators of 
oxidative stress in lab animals (Chisolm & Steinberg, 2000) and (iii) the incidence of CVD in 
individuals with low concentrations of antioxidants is relatively high (Chisolm and Steinberg, 
2000). These (and other) findings and clinical trials led researchers to two assumptions: (i) 
oxidative stress plays a pivotal role in the formation of atherogenic plaque and (ii) individuals 
with prevalent CVD are likely to be under oxidative stress and therefore have high plasma 
concentrations of lipid peroxidation products and loss of LMWA. 
The first assumption has long been disputed and is currently under scrutiny (Williams & 
Fisher, 2005). The second assumption is weakened by the results of our current meta-
analysis, which shows that the prevalence of CVD is only slightly associated with OS, as 
defined on the basis MDA concentration. By contrast, no evidence is available for 
association between CVD and OS, as determined on the basis of all other indices of 
oxidative stress. Specifically, the concentrations of almost all the micronutrients in the 
plasma of CVD patients are within normal ranges (Fig. 2), the activities of relevant enzymes 
did not differ from those observed in matched controls (Fig. 2). The same results were 
observed for most of the indices of lipid peroxidation. The only index that is significantly 
different with the prevalence of CVD is the plasma concentration of MDA. Even if we 
choose to ignore the reservations regarding the use of MDA as an index of lipid 
peroxidation (Draper et al., 1993), the possibility of publication bias should not be ignored. 
Hence, we think that the existing evidence for association between oxidative stress and the 
prevalence of CVD is quite weak. In other words, it appears that the role of oxidative stress 
in atherogenesis has been overestimated. In accordance with this conclusion, is the 
viewpoint of the recent review, regarding association of several more OS indices (circulation 
levels of oxidized LDL and myeloperoxidase) with CVD (Strobel et al., 2011). The authors 
conclude that “results of studies using Ox-LDL have been equivocal” and that “the ability of 
oxidative stress biomarkers to predict CVD has yet to be established”. 
The latter considerations accord with the current trend in cardiovascular disease research, 
which views atherosclerosis as mostly an inflammatory disease (Ross, 1999) and implies 
that oxidative stress is a result and not the cause for atherosclerosis. This trend also 
accords with and therefore is strengthened by two of our findings: (i) we observed that 
patients with UAP, a condition commonly associated with acute inflammation, are under 
higher “oxidative stress”, as assessed by the serum concentration of MDA, than both 
patients with SAP and matched controls (Fig. 3) and (ii) we observed that studies 
including more acute conditions are under higher “oxidative stress” than matched 
controls (Fig. 4). 
In our opinion, these findings are of little relevance to the possibility that many individuals 
may benefit from antioxidant supplementation. 
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Our ongoing research is aimed at developing such an assay (or assays) that can serve as a 
basis for selective antioxidant supplementation. Our working hypothesis is a two step 
approach of identifying those individuals that may benefit from antioxidant 
supplementation. The first step is an initial, short-term treatment with vitamin E. The 
second step should be to assess plasma concentrations of lipid peroxidation products and to 
continue treatment with vitamin E only to individuals, responding to treatment by reducing 
significantly plasma concentration of lipid peroxidation products. In conclusion, we have no 
evidence that justify indiscriminate supplementation of vitamin E, nor do we have sufficient 
evidence to ban it, as recommended by the authors of the Cache County Study (Hayden et 
al., 2007). At present we have no assay that can be used to identify patients that are likely to 
benefit from Vitamin E supplementation. 
 
 
Fig. 4. A forest plot comparing two strata of studies. The first stratum compares the 
differences between patients with either stable angina pectoris or mild occlusions of the 
coronary arteries and healthy controls. The second stratum compares the differences 
between patients with either unstable angina pectoris or MI and healthy controls. Notably, 
while the first stratum of patients with SAP varies slightly from healthy controls, the second 
stratum of patients with UAP shows a significant difference. The two strata differ 
significantly (p = 0.02). 
5. Conclusion 
Our meta-analysis shows that the commonly accepted paradigm regarding the role of OS in 
the pathogenesis of CVD appears to be overestimated. CVD is associated with OS only 
when the evaluation of OS is based on plasma concentrations of MDA. Notably, even this 
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association is questionable due to (i) poor reliability of the laboratory assay of MDA and (ii) 
publication bias. 
Most of the clinical trials that were designed to reduce OS by means of antioxidant 
supplementation yielded disappointing results. The latter results are consistent with the 
results of our meta-analysis. Hence, oxidative stress is only weakly associated with the 
prevalence of cardiovascular disease.  
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